{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-032403","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.412758+00:00","generated_at":"2026-05-15T09:29:13.916238+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relmada FY2025 net loss $57.4M; NDV-01 76% CR at 12 months; $160M PIPE closed","bullets":["FY2025 net loss $57.4M ($1.45/share) vs $80.0M in FY2024; Q4 net loss $19.9M ($0.27/share).","NDV-01 Phase 2: 95% CR at any time, 76% durable CR at 12 months in high-risk NMIBC; BCG-unresponsive 80% CR at 12 months.","Oversubscribed $160M PIPE closed March 2026; cash $93M at Dec 31, 2025 plus PIPE expected to fund operations through 2029.","R&D expense $26.9M (down from $46.2M); G&A $32.2M (down from $37.7M); shares outstanding 104.9M.","On track to start Phase 3 RESCUE program and Sepranolone Phase 2 in Prader-Willi mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-032403","json":"https://secwatch.observer/filing/0001213900-26-032403.json","markdown":"https://secwatch.observer/filing/0001213900-26-032403.md","text":"https://secwatch.observer/filing/0001213900-26-032403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/0001213900-26-032403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/ea0282688-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:29:13.916238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fc3f11bf0251cd3136d34b7d9036ec2c32c761c","claim":"RELMADA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2025.","evidence_excerpt":"Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/0001213900-26-032403-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}